BREAKING NEWS
Cloud Server Hosting For Online Businesses
Inexpensive SEO Services
Benefits of Wanting to play Free Online Slot machines
Motavizumab

Summary

Motavizumab (proposed INN, trade name Numax) is a humanized monoclonal antibody. It is being investigated by MedImmune (today a subsidiary of AstraZeneca) for the prevention of respiratory syncytial virus infection in high-risk infants.[1] As of September 2009, it is undergoing Phase II and III clinical trials.[2]

Motavizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetRSV glycoprotein F
Clinical data
Trade namesNumax
Routes of
administration		Intravenous
ATC code
Pharmacokinetic data
Protein bindingNone
Identifiers
CAS Number
  • 677010-34-3 ☒N
DrugBank
  • DB06310 checkY
ChemSpider
  • none
UNII
  • 50Y163LK8Q
KEGG
  • D06621 checkY
Chemical and physical data
FormulaC6476H10014N1706O2008S48
Molar mass145438.16 g·mol−1
 ☒NcheckY (what is this?)  (verify)

In June 2010, the FDA Antiviral Drugs Advisory Committee declined to endorse MedImmune's request for licensure of Motavizumab in a 14 to 3 decision. The members of that panel cited several reasons for the decision, and many were concerned that "we're not looking at a product that has evidence of superiority in terms of efficacy" when compared to the already available monoclonal antibody Palivizumab.[3]

In December 2010, AstraZeneca in a stock market statement stated that it would be writing down $445m (£286m) after discontinuing a key development programme for Motavizumab. The company stated that it would no longer develop Motavizumab for the prevention of respiratory syncytial virus (RSV), and as a result was withdrawing its licence application to the US Food and Drug Administration. It added that it would continue to develop Motavizumab for other treatments of RSV.[4]

References edit

  1. ^ Kalergis AM, Soto JA, Gálvez NM, Andrade CA, Fernandez A, Bohmwald K, Bueno SM (December 2020). "Pharmacological management of human respiratory syncytial virus infection". Expert Opinion on Pharmacotherapy. 21 (18): 2293–2303. doi:10.1080/14656566.2020.1806821. PMID 32808830. S2CID 221163435.
  2. ^ ClinicalTrials.gov
  3. ^ "FDA Panel Nixes Licensing Request for Motavizumab". Medscape. 3 June 2010. Retrieved 2014-03-02.
  4. ^ "AstraZeneca halts work on Motavizumab drug". BBC News. 21 December 2010. Retrieved 2010-12-21.

External links edit

  • "Motavizumab". Drug Information Portal. U.S. National Library of Medicine.